mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

Partnershipemicizumab biosimilarPositive

AI Analysis

Summary

mAbxience and Sandoz have signed a collaboration agreement to jointly develop and commercialize an emicizumab biosimilar candidate for haemophilia A, combining mAbxience's manufacturing expertise with Sandoz's global commercial capabilities.

Importance:6/10

Sentiment:

0.60

biosimilarcollaborationpartnershiphaemophiliamanufacturing

Related Companies

$SDZ.SW

Read the original article

Published by PR Newswire Biotech on September 18, 2026 10:16 AM

Read Original